Suggested remit - To appraise the clinical and cost effectiveness of trifluridine-tipiracil within its marketing authorisation for previously treated metastatic gastric or gastro-oesophageal junction cancer
 
Status In progress
Process STA 2018
ID number 1507

Project Team

Project lead Louise Jafferally

Email enquiries

Evidence Review Group / Assessment Group School of Health and Related Research (ScHARR), University of Sheffield

Consultees

Companies sponsors Servier laboratories (trifluridine-tipiracil hydrochloride)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Professional groups Association of Cancer Physicians
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists

Commentators

Comparator companies Accord Healthcare (docetaxel, paclitaxel) – confidentiality form not signed
  Celgene (paclitaxel) – confidentiality form not signed
  Genzyme (docetaxel) – confidentiality form not signed
  Hospira UK (docetaxel, paclitaxel) – confidentiality form not signed
  Medac (docetaxel, paclitaxel) – confidentiality form not signed
  Seacross Pharmaceuticals (docetaxel) – confidentiality form not signed
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
10 May 2019 In progress, Referred 24 April 2018
05 April 2019 Invitation to participate
30 January 2019 - 27 February 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance